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Abstract
The correspondence of cell state changes in diseased organs to
peripheral protein signatures is currently unknown. Here, we
generated and integrated single-cell transcriptomic and proteomic
data from multiple large pulmonary fibrosis patient cohorts. Inte-
gration of 233,638 single-cell transcriptomes (n = 61) across three
independent cohorts enabled us to derive shifts in cell type propor-
tions and a robust core set of genes altered in lung fibrosis for 45
cell types. Mass spectrometry analysis of lung lavage fluid
(n = 124) and plasma (n = 141) proteomes identified distinct
protein signatures correlated with diagnosis, lung function, and
injury status. A novel SSTR2+ pericyte state correlated with disease
severity and was reflected in lavage fluid by increased levels of the
complement regulatory factor CFHR1. We further discovered
CRTAC1 as a biomarker of alveolar type-2 epithelial cell health
status in lavage fluid and plasma. Using cross-modal analysis and
machine learning, we identified the cellular source of biomarkers
and demonstrated that information transfer between modalities
correctly predicts disease status, suggesting feasibility of clinical
cell state monitoring through longitudinal sampling of body fluid
proteomes.
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Introduction
The accumulation and persistence of scar tissue in fibrotic diseases
such as pulmonary fibrosis, liver cirrhosis, and cardiovascular
disease is among the most severe clinical issues, causing an esti-
mated 45% of all deaths in the developed world (Cox & Erler,
2011). Interstitial lung diseases (ILDs) are a heterogeneous group of
diseases ultimately leading to pulmonary fibrosis, which can cause
severe destruction of the lung parenchyma and respiratory failure.
Several potential risk factors have been identified, including genetic
predisposition (Allen et al, 2019), smoking (Baumgartner et al,
1997), infections (e.g., viruses) (Sheng et al, 2019), aging (Selman
et al, 2016), and autoimmunity (Fischer & du Bois, 2012; Schiller
et al, 2017). Addressing the heterogeneity of ILD entities, disease
progression and prognosis, and the currently unpredictable occur-
rence of acute exacerbations of disease, require new molecular
approaches for personalized patient monitoring.
The recent surge of innovation in single-cell genomics enables an
entirely novel cell type-specific viewpoint on pathological changes
1 Institute of Lung Biology and Disease and Comprehensive Pneumology Center with the CPC–M bioArchive, Helmholtz Zentrum M€unchen, Member of the German Center
for Lung Research (DZL), Munich, Germany
2 Institute of Computational Biology, Helmholtz Zentrum M€unchen, Munich, Germany
3 Department of Internal Medicine V, Ludwig-Maximilians University (LMU) Munich, Member of the German Center for Lung Research (DZL), CPC-M bioArchive, Munich,
Germany
4 Department of Rheumatology, Center of Experimental Rheumatology, University & University Hospital Zurich, Zurich, Switzerland
5 Department of Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Martinsried, Germany
6 Asklepios Fachkliniken Munich-Gauting, CPC-M bioArchive, Member of the German Center for Lung Research (DZL), Munich, Germany
7 Faculty of Medicine, Max von Pettenkofer-Institute, Virology, National Reference Center for Retroviruses, LMU M€unchen, Munich, Germany
8 Helmholtz Zentrum M€unchen, Research Unit Lung Repair and Regeneration, Member of the German Center for Lung Research (DZL), Munich, Germany
9 University Department of Visceral and Thoracic Surgery Salzburg, Paracelsus Medical University, Salzburg, Austria
10 Center for Comprehensive Developmental Care (CDeCLMU), Member of the German Center for Lung Research (DZL), Hospital of the Ludwig-Maximilians University (LMU),
CPC-M bioArchive, Munich, Germany
11 Department of Pneumology, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany
12 Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA
*Corresponding author. Tel: +49 89 3187 43260; E-mail: fabian.theis@helmholtz-muenchen.de
**Corresponding author. Tel: +49 89 3187 1194; E-mail: herbert.schiller@helmholtz-muenchen.de
†These authors contributed equally to this work
ª 2021 The Authors. Published under the terms of the CC BY 4.0 license EMBO Molecular Medicine 13: e12871 | 2021 1 of 22
in disease. Based on these new technologies, the Human Cell Atlas
project aims at building a comprehensive reference map of all
human cells as a basis for understanding fundamental human
biological processes and diagnosing, monitoring, and treating
disease. This includes recent international efforts toward building a
human Lung Cell Atlas in health and disease (Schiller et al, 2019). A
first draft of the cellular composition of mouse and human lung has
been established (Han et al, 2018; Tabula Muris Consortium et al,
2018; Vieira Braga et al, 2019; Angelidis et al, 2019; Travaglini et al,
2020), and several recent single-cell profiling studies reported cellu-
lar and molecular changes associated with pulmonary fibrosis (Reyf-
man et al, 2019; Morse et al, 2019). However, this nascent draft of a
human Lung Cell Atlas currently lacks extension into the complexity
of the proteome layer and integrated analysis of gene expression dif-
ferences across large numbers of patients.
As disease trajectories in ILD patients are often highly variable,
protein signatures in patient body fluids promise improved person-
alized treatment and longitudinal monitoring of patients (Maher
et al, 2017; Neighbors et al, 2018). The transcriptomic and
proteomic changes in end-stage ILD patient lung tissue have been
resolved using microarrays, RNA-sequencing, and mass spectrome-
try (Zuo et al, 2002; Schiller et al, 2017; McDonough et al, 2019).
Furthermore, first gene and protein expression signatures in ILD
bronchoalveolar lavage (BAL), which is obtained during bron-
choscopy, have been analyzed (Foster et al, 2015; Prasse et al,
2019). Currently, it is unclear which cellular and molecular
processes in the lung correspond to these biomarker signatures,
representing a tissue or fluid average which does not resolve cellular
composition and disease-specific cell states.
In this work, we explore the idea that protein signatures found in
bronchoalveolar lavage and plasma, both of which are accessible
for longitudinal monitoring of patients, can be used to predict patho-
logical cell state changes in the lung. We aimed at establishing a
first proof of concept for this approach, which has relevance for
future predictive and interceptive medicine (Rajewsky et al, 2020).
Our analysis dissects human lung fibrosis at the single-cell level,
defining robust differential gene expression profiles and cell
frequency changes across multiple studies for ILD. Using mass spec-
trometry, we discover protein biomarker signatures associated with
diagnosis, lung function, and injury status and predict the cellular
sources of these protein signatures based on single-cell analysis.
Using machine learning, we show that fluid proteome signatures are
predictive of specific cell state changes in the lung.
Results
An integrated single-cell atlas of human lung fibrosis
To analyze transcriptional changes in lung fibrosis at cellular resolu-
tion, we obtained whole lung parenchyma single-cell suspensions
using end-stage lung fibrosis tissues from three ILD patients (IPF
n = 2, EAA n = 1) and non-fibrotic control tissues from 11 non-lung
disease patients for comparison (further referred to as controls).
Dimension reduction was used to visualize a data manifold repre-
senting the gene expression space of 41,888 single-cells, generated
by using the Drop-seq workflow (Macosko et al, 2015; Fig 1A and
B; control, n = 11; ILD, n = 3) (Appendix Fig S1A and B). We
generated subsets of the whole lung parenchyma datasets for
COL1A2+ stromal cells (Fig 1C and Appendix Fig S1C–E), EPCAM+
epithelial cells (Fig 1D and Appendix Fig S1F–H), CLDN5+ endothe-
lial cells (Fig 1E and Appendix Fig S1I–K), and CD45+ leukocytes
(Fig 1F and Appendix Fig S1L–N). From these subsets, we derived
cluster identities (Appendix Fig S1; Dataset EV1) that were manually
annotated using previously established single-cell signatures in the
human lung (Vieira Braga et al, 2019; Travaglini et al, 2020). The
final annotation revealed 45 cell type identities, characterized by
unique marker gene expression profiles (Fig 1G–J) that were to
some extent preserved in end-stage fibrosis.
To increase statistical power, and ensure generalizability and
reproducibility of our results, we integrated our dataset with two
large publicly available single-cell RNA-seq (scRNA-seq) datasets.
Using the BBKNN method (Polanski et al, 2020), we calculated an
integrated data manifold (as described in Materials and Methods)
that represents gene expression profiles of 233,638 single-cells from
61 human individuals (ILD n = 32, controls n = 29) from all three
studies (Fig 2A and B; Reyfman et al, 2019)—Chicago cohort: ILD
n = 9, controls n = 8; Nashville cohort: ILD n = 20, controls n = 10;
and Munich cohort: ILD n = 3, controls n = 11. Cell type identities
were then annotated manually as described above (Fig 2C; Dataset
EV2).
Next, we performed cell type-specific differential gene expression
analysis accounting for demographic covariates across all 61 indi-
viduals. As a proof of concept, we first identified genes significantly
associated with gender. The top hits were genes located on one of
the sex chromosomes, demonstrating the validity of our approach
(Appendix Fig S2A and B). Next, we identified genes differentially
expressed between end-stage lung fibrosis and control tissue
accounting for age, gender and study cohort (see Dataset EV4a for a
full list of differential gene expression for health status stratified by
cell type or by meta-cell type in Dataset EV4b). Gene expression
changes in disease were most similar in cell types within the respec-
tive epithelial, mesenchymal, and leukocyte lineages (Fig 2D). This
means that, for instance, the up- and downregulated genes in fibrob-
lasts are more likely to be also regulated in other mesenchymal cells
as in leukocytes and vice versa. Despite small differences in
sequencing depth, differentially expressed genes showed very good
agreement between the three independent patient cohorts (Fig 2E–
H). The upregulated KRT17 gene (Fig 2F) in alveolar epithelial cells
was recently defined as a marker for the novel aberrant basaloid
cells in IPF (Adams et al, 2020; Habermann et al, 2020). These
fibrosis-specific cells feature a cellular senescence signature
(Kobayashi et al, 2020), including high expression of CDKN2A (en-
coding for p16; Fig 2F). We also corroborate previous studies by
showing that in fibroblasts (Fig 2G) the expression levels of DIO2,
encoding for the thyroid hormone activating enzyme iodothyronine
deiodinase (Yu et al, 2017), and the circulating CXCL14 (Jia et al,
2017; Rodriguez et al, 2018) chemokine are increased. In macro-
phages (Fig 2H), the normal alveolar macrophage phenotype that is
marked by high FABP4 expression is replaced by an ILD-associated
cell state that features high expression of SPP1 (Osteopontin) (Morse
et al, 2019), which we termed activated AM. These cells also
express higher levels of the CCR2 ligand CCL7, which is a chemoat-
tractant potentially involved in the recruitment of fibrocytes and
profibrotic macrophages (Moore et al, 2005; Osterholzer et al, 2012,
2013). These examples manifest that integration of scRNA-seq
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datasets facilitates highly powered and robust differential gene
expression analysis, which represents a valuable resource to the
research community.
Differences in cell type frequencies between individual samples
can be caused by true biological differences, as well as differences
in cell isolation protocols and scRNA-seq platforms used. Indeed,
we observed large variance in cell population frequencies across
cohorts and disease conditions (Appendix Fig S2C). After perform-
ing dimension reduction using PCA, we observed larger variation in
principal components one and two among ILD patients compared to
control samples, indicating increased heterogeneity in disease
(Fig 3A). Principal component two separated samples obtained from
control donors and ILD patients across all three cohorts (Fig 3B).
This observation motivated us to ask if cell type frequencies alone
could distinguish ILD samples from controls. Therefore, we trained
a random forest model based on the cell type proportions to predict
disease status. This model achieved a mean accuracy of 83%
derived from fivefold cross-validation (Fig 3C), demonstrating that
the cell type frequencies showed robust differences in disease. Most
important for the models prediction accuracy were changes in
A





Figure 1. Single-cell analysis of human lung parenchyma reveals 45 distinct cell type identities and their marker genes in ILD.
A, B Dimension-reduced single-cell transcriptomic data are visualized through Uniform Manifold Approximation and Projection (UMAP). The color code illustrates the
disease status (A) and cell type identity (B) (see Dataset EV3 for abbreviations).
C–F The indicated marker genes were used to select clusters for subsetting into stromal cells (C), epithelial cells (D), endothelial cells (E), and leukocytes (F).
G–J The heatmaps show the relative gene expression levels for the indicated marker genes for the indicated stromal (G), epithelial (H), endothelial (I), and leukocyte (J)
cell types.
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frequency of disease induced cell states as well as several parenchy-
mal cell identities (Fig 3D). As expected, the decrease of AT1 and
AT2 cells was important for the predictions. Interestingly, the top
importance score in the model was achieved by the recently discov-
ered aberrant basaloid cells (Adams et al, 2020; Habermann et al,
2020), suggesting that this cell state is indeed very disease-specific
(Fig 3D).
To leverage the power of bulk RNA-seq data archived in public
databases, we used our ILD single-cell atlas to determine possible
cell type frequency changes in such datasets. A recent study used
quantitative micro-CT imaging and tissue histology on biopsies to
stratify lung tissue of idiopathic pulmonary fibrosis (IPF) patients
into different stages (IPF stage 1–3) marked by increasing extent of
fibrotic remodeling (lower alveolar surface density and higher colla-
gen content) (McDonough et al, 2019). Thus, the RNA-seq profiles
of these staged patient samples presumably depict disease progres-
sion within patients. We calculated enrichment of our cell state
signatures across the three stages of IPF progression and observed
significant changes of many cell types already in early stage IPF-1,
which still harbors more alveolar cell identities compared to the
more advanced stages IPF-2 and IPF-3 (Fig 3E). This included the
myofibroblast signature (Fig 3F) that was clearly upregulated early
in progression as well as the aberrant basaloid cells. Other cell





Figure 2. Multi-cohort single-cell data reveal reproducible transcriptional changes for > 40 cell types.
A–C Dimension-reduced single-cell transcriptomic data are visualized through multiple Uniform Manifold Approximation and Projections (UMAPs). The colors illustrate
(A) patient cohorts, (B) disease status, (C) and cell type identity (see Table S3 for abbreviations).
D Differential gene expression between end-stage lung disease patients and controls across cohorts was compared for the indicated cell type identities. The color
code demonstrates similarities of gene expression changes calculated by Pearson correlation of the t-value coefficient, which represents differences in the
likelihood of detection for any gene between health and disease.
E The heatmap shows the top 79 genes differentially expressed in the indicated cell type identities.
F–H The box plots illustrate differences in mRNA detection for the indicated genes between tissues from end-stage lung fibrosis patients in (F) alveolar epithelial cells,
(G) fibroblasts, and (H) macrophages when compared to control tissue. The boxes represent the interquartile range, the horizontal line in the box is the median,
and the whiskers represent 1.5 times the interquartile range (Chicago cohort: ILD n = 9, controls n = 8; Nashville cohort: ILD n = 20, controls n = 10; Munich
cohort: ILD n = 3, controls n = 11).
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from IPF1 to IPF3, while for instance the increase in ciliated cell
frequency was observed only from IPF stage 2 onwards (Fig 3F).
Increases in airway cell frequencies with advanced stages are likely
the consequence of the well described “bronchiolization” of the
distal lung with metaplastic epithelial cells in IPF. Importantly, our
analysis identifies cell state shifts and cell frequency changes that
precede this bronchiolization. The appearance of the aberrant basa-
loid cells together with activated fibroblast states peaked already at
the IPF-1 stage, indicating that these represent early events in
disease progression. Notably, also several immune cell types,
including B and T lymphocytes, were increased already in IPF-1.
In summary, we computationally integrated over 200 thousand
single-cells from three independent lung fibrosis patient cohorts.
Differential gene expression in lung fibrosis was robustly replicated
and validated across cohorts and thus serves as a powerful resource
to investigators studying ILD pathogenesis and progression, e.g., for
the dissection of bulk RNA-seq profiles as demonstrated. We show
that cell state changes as well as cell type frequency changes co-
occur during disease progression and can be decoupled using single-
cell analysis.
Human lung bronchoalveolar lavage fluid proteomes reflect
changes in disease activity
Transcriptional changes are not always correlated with protein
abundance, in particular if proteins are secreted (Angelidis et al,
2019). However, some of the cell state changes described by our
single-cell analysis may be reflected in the proteomic composition
of the bronchoalveolar lavage fluid (BALF), which is accessible for
sampling during bronchoscopic examination of patients. Here, we
used state-of-the-art mass spectrometry for in-depth analysis of
BALF proteomes of a large ILD and non-ILD patient cohort
(Fig 4A). Our ILD cohort included eight groups of patients
(Fig 4B), with a diagnosis of idiopathic pulmonary fibrosis (IPF,
n = 16), hypersensitivity pneumonitis (HP/EAA, n = 8), crypto-
genic organizing pneumonia (COP, n = 11), idiopathic non-specific
interstitial pneumonia (NSIP, n = 10), smoking-associated respira-
tory bronchiolitis ILD (RB-ILD, n = 3), Sarcoidosis (n = 22),
unclassifiable ILDs (other ILDs, n = 25), or non-ILD conditions
such as lung cancer or COPD (non-ILD, n = 29) (see Dataset EV5
for clinical features). Of note, the majority of lavage fluids from
patients in this cohort were collected during evaluation of initial
diagnosis of ILD and thus rather represent early disease. Nonethe-
less, some patients already had severely reduced lung function.
From 124 patients (95 ILD and 29 non-ILD) that passed quality
control criteria, we quantified a median number of 835 proteins
per individual patient, resulting in a total of 1,513 unique proteins
that were quantified in at least 20 patients (Fig 4B and Dataset
EV6). This is a very good depth of analysis given that BALF is dif-
ficult to analyze by mass spectrometry because of the high
dynamic range of protein copy numbers present due to plasma
protein leakage. To illustrate a correlation of the extent of plasma
protein leakage with the depth of proteome analysis in our BALF
samples, we quantified the mass fraction of the top 100 abundant
proteins in patient plasma in the BALF proteomes. The number of
detected proteins in BALF inversely correlated with the relative
proportion of plasma proteins present (Appendix Fig S3A);
however, this was not strongly associated with plasma LDH, which
serves as a marker for tissue damage in patient blood. Using a
quantitative comparison of proteins detected in both the ILD
patient plasma and BALF proteomes revealed proteins that are
detected in plasma proteomes but are quantitatively enriched in
BALF, suggesting they are produced locally in the lung and then
transpire to the plasma (Appendix Fig S3B).
To better define the proteins that are major constituents of the
epithelial lining fluid (ELF) of the lung (rather than tissue leakage
proteins), we also performed a quantitative comparison of BALF
content and total tissue proteomes from 11 end-stage ILD tissue
biopsies (Schiller et al, 2017). Proteins detected in both tissue and
fluid proteomes were scored as either a “tissue leakage” protein or
“epithelial lining fluid” protein based on their enrichments in the
respective compartments (Appendix Fig S3C). Indeed, proteins
specific for secretory epithelial cells such as Club and AT2 cells had
a significantly higher ELF enrichment score as proteins specific to
non-secretory AT1 cells. Similarly, we found that secreted proteins
had a higher score than transmembrane proteins and cytoplasmic
proteins (Appendix Fig S3D). We identified 7 proteins that were
significantly associated with clinical parameters, had a high ELF
score, and were also detected in patient plasma by mass spectrome-
try (Appendix Fig S3E). Mapping the expression of these genes on
the individual cell type identities illustrates their specific expression
patterns (Appendix Fig S3F).
A Fisher’s exact test showed that 285 BALF proteins with high
coefficient of variation (CV) across patients (Appendix Fig S4A)
were significantly enriched for gene annotations such as “secreted”,
“plasma lipoprotein”, “antimicrobial”, “nucleosome”, “intermediate
filament”, and “extracellular matrix” (Dataset EV7), indicating that
these categories are regulated across patient groups. Principal
component analysis revealed clusters of patients with heteroge-
neous diagnosis that were either significantly enriched in comple-
ment, coagulation proteins and plasma lipid transport proteins, or
showed higher levels of antimicrobial proteins and histones, point-
ing toward the involvement of an inflammatory response driven by
neutrophil extracellular traps (NETs) in these patients
(Appendix Fig S4B and C). Correlation analysis of the protein
expression profiles revealed that in fact many proteins were co-
expressed across patients, revealing co-regulated protein modules
that were enriched for distinct signatures, including macrophage
specific proteins such as the Scavenger receptor cysteine-rich type 1
protein M130 (CD163) and the Complement C1q subcomponent
subunit C (C1QC), wound healing factors, such as the ECM proteins
Tenascin-C, Fibronectin, Collagen type 6 and Periostin, as well as
lipid transport, complement and coagulation proteins such as
Apolipoprotein B-100 and Complement component C7, or antimicro-
bial defense and neutrophil chemotaxis factors, including granulo-
cyte specific proteins such as S100-A8, S100-A9, Cathelicidin
antimicrobial peptide (CAMP) and Myeloperoxidase (MPO)
(Appendix Fig S4D).
In correlation analysis, we identified associations of these protein
signatures with 33 individual clinical measurements per patient,
including various lung function parameters and plasma LDH
(Dataset EV8 and Appendix Figs S5 and S6). We identified
biomarker signatures by Pearson correlation of the clinical parame-
ters with proteins that were quantified in BALF in at least 20
patients (Dataset EV6), revealing highly significant correlations of
distinct sets of proteins with several lung function parameters,
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including Diffusing Capacity For Carbon Monoxide (DLCO) or
plasma levels for lactate dehydrogenase (pLDH) (Fig 4C). Most
proteins that we found increased in BALF of patients with high
pLDH were also associated with lower lung function (Appendix Fig
S6A), and top outliers remained significant after accounting for
patient age (Appendix Fig S6B–E). Because LDH is released during
tissue damage and transpires to the blood, its levels in blood plasma
are clinically used as a marker of ongoing cell death in tissues. We
hypothesized that BALF proteins with correlation to pLDH in human
patients represent a lung injury signature. A comparison of the
human pLDH signature with BALF proteomes from mice after bleo-
mycin injury revealed similar outlier proteins across species includ-
ing the injury marker Tenascin-C (Appendix Fig S6F). Using 1D
annotation enrichment analysis (see Materials and Methods), we
confirmed that the pLDH correlation revealed protein changes in
human patient BALF proteomes that were highly similar to the ones
that can be observed upon a defined acute lung injury in the bleo-
mycin mouse model (Appendix Fig S6G).
To maximize the utility of this densely phenotyped cohort, we
used principal component analysis to derive a single measure of
“meta” lung function representing the combination of multiple lung
function parameters (Fig 4D). Next, to account for potential
confounding demographic variables, we performed linear multivari-
ate regression analysis associating protein expression levels with the
meta lung function variable accounting for age and gender (Fig 3E,
Dataset EV9).
In summary, we analyzed BALF proteomes from 124 patients
and correlated protein expression with an extensive set of clinical
parameters, which represents, to the best of our knowledge, the
most comprehensive characterization of this body fluid so far.
Further, we identified co-regulated protein modules that were asso-




Figure 3. Disease progression alters cell type frequencies.
A Principal components one (x-axis) and two (y-axis) illustrate the cell type frequencies in reduced dimensions. The shape of each point corresponds to the study
cohort, and the points are colored by disease phenotype.
B Box plots display principal component two across ILD patients (orange) and control samples (purple) for the three study cohorts. The boxes represent the interquartile
range, the horizontal line in the box is the median, and the whiskers represent 1.5 times the interquartile range (Chicago cohort: ILD n = 9, controls n = 8; Nashville
cohort: ILD n = 20, controls n = 10; Munich cohort: ILD n = 3, controls n = 11).
C Box plot depicts random forest model prediction accuracies derived from fivefold cross-validation using the original and permuted labels. The boxes represent the
interquartile range, the horizontal line in the box is the median, and the whiskers represent 1.5 times the interquartile range (n = 5).
D Barplot shows the random forest importance scores for the top ten most informative features.
E The heatmap shows changes of the indicated cell type signatures in published bulk RNA-seq data (GEO GSE124685) across different histopathological stages that
represent increasing extent of fibrosis from stage 1–3, as determined by quantitative micro-CT imaging and tissue histology (McDonough et al, 2019). Samples used in
this study were 10 IPF and 6 control patients.
F The heatmaps show z-scores for the individual marker genes of the indicated cell types across IPF stages and controls.
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suggesting that some of these protein signatures could be used to
monitor acute or subclinical exacerbations of ILD patients.
Correspondence of fluid proteins with cell state and frequency
changes in the lung
Next, we aimed to explain quantitative changes in BALF protein
signatures with the cell state changes analyzed by single-cell RNA-
seq. We first deconvoluted the diagnosis-specific protein biomarker
signatures in the BALF proteomes and evaluated the relative contri-
bution of cell types/states. Mean intensity z-scores of proteins
across different diagnostic groups were tested for enrichment of cell
type-specific transcriptional signatures (Fig 5A). Markers of several
pro-fibrogenic cell types including fibroblast subsets, pericytes,
plasma cells, and mesothelial cells were strongly increased in
protein measurements of COP, NSIP, HP/EAA, and IPF compared to
non-ILD controls, confirming the power of BALF proteomics to
correctly score fibrogenic remodeling in the patients. Interestingly,
RB-ILD and Sarcoidosis samples were similar to non-ILD controls
for this signature, which is consistent with their distinct histopathol-
ogy that does not involve strong interstitial fibrosis. While RB-ILD
protein analysis featured very strong enrichment for proteins speci-
fic to airway basal, ciliated, and goblet cells, the same airway
protein signature was depleted in patients with COP, NSIP, and HP/
EAA but not IPF (Fig 5A).
Similarly, we found strong associations between cell type/state
signatures and the Pearson correlation of most clinical parameters






Figure 4. Human lung bronchoalveolar lavage fluid proteome changes correlate with clinical parameters.
A Proteomics workflow.
B The box plots show the number of proteins quantified (y-axis) across various diagnoses (x-axis). The mean and 10–90 percentiles are shown; the dotted line marks
1,000 proteins (IPF n = 16, HP/EAA n = 8, COP n = 11, NSIP n = 10, RB-IL, n = 3, Sarcoidosis n = 22, other ILDs n = 25, non-IL, n = 29).
C The heatmap shows the correlation coefficients between proteins (rows) and clinical parameters (columns).
D The heatmap illustrates the computationally derived meta lung function variable combining multiple lung function parameters.
E The volcano plot shows the multivariate regression coefficients (x-axis) and the log10 P-value (y-axis) for BALF protein abundance with the meta lung function.
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myofibroblast-specific proteins quantified in patient BALF tended to
be negatively correlated with lung function (DLCO) (Fig 5C), and
the number of alveolar macrophages in BAL cytospins tended to be
negatively correlated with proteins (mostly antibodies) secreted by
plasma cells into the BALF (Fig 5D).
Next, we aimed to understand the relationship between cell type-
specific transcriptional changes and distinct signatures in the bron-
choalveolar lavage fluid. To accomplish this aim, we integrated the
results from two multivariate regression analyses: (i) protein associ-
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associations with ILD status. Correlation of the t-values derived
from both regressions revealed that the greatest correspondence
between protein signatures associated with meta lung function and
expression changes occured in club and basal cells as well as the
alveolar epithelium (Fig 5E). However, the measured bulk protein
profiles in BALF can be affected by two types of alterations: (i)
changes in cell type frequency and (ii) changes in gene expression.
Therefore, we inferred cell type frequency changes by performing
deconvolution analysis on a large bulk expression dataset contain-
ing ILD patients and healthy controls from the Lung Tissue Research
Consortium (LTRC; GSE47460). The top regulated BALF proteins
were often altered both on gene expression and cell type frequency
levels (Fig 5F), which importantly can be distinguished using
scRNA-seq data.
Finally, to test if we could successfully transfer information from
the proteomics modality into the scRNA-seq data modality, we
applied machine learning. A random forest was trained on the
protein quantification data to predict lung function (DLCO) using a
set of protein features which (i) showed high correlation with lung
function (DLCO) and (ii) had the corresponding transcript detected
in the scRNA-seq data. Next, the trained model was applied to in
silico bulk scRNA-seq data with mRNA expression mapped to
proteins (Fig 5G), which then correctly predicted the direction of
lung function changes in the three single-cell RNA-seq cohorts
(Fig 5H). In addition, we applied an analogous approach to
published bulk RNA-seq data of IPF samples from different
histopathological stages determined by quantitative micro-CT imag-
ing and tissue histology (GEO GSE124685) (McDonough et al, 2019;
Fig 5I). Our model successfully predicted continuous lung function
decline along the histopathological IPF disease stages, indicating
that the BALF protein biomarker profiles discovered in this study
quantitatively reflect cell state changes during disease progression.
Stratification along the protein and cell type-specific t-values
revealed the expected inverse correlations between protein associa-
tion with meta lung function and upregulation of the corresponding
gene in ILD for several cell types, including KRT5+ basal cells and
alveolar epithelial cells (Fig 6A–F). To histologically validate some
of the most significantly regulated proteins in BALF and put these
into the context of the cell types identified by scRNA-seq, we
performed immunofluorescence analysis (Fig 6G–J). Increased
expression of the extracellular matrix protein Tenascin-C, which is a
known marker in tissue repair and was also upregulated in mouse
lung injury (Appendix Fig S6F), was found in IPF tissue sections in
KRT5+ basal cells in the “bronchiolized” distal lung (Fig 6G). As
predicted by the scRNA-seq analysis, these cells also co-expressed
increased levels of the 14-3-3 protein sigma (SFN), which is an
adaptor protein with possible functions in epithelial cell growth and
regulation of the p53 pathway (Yang et al, 2008; Fig 6H and I). SFN
has recently also been described as a marker in a novel transitional
stem cell state that transiently appears during lung regeneration
(Strunz et al, 2020; Kobayashi et al, 2020). This transitional stem
cell state is highly similar to the aberrant basaloid state discovered
in IPF (Adams et al, 2020; Habermann et al, 2020), which also
expresses increased amounts of SFN. The transitional stem cell state
in lung injury repair is also characterized by increased levels of
KRT8 expression (Strunz et al, 2020), and interestingly, we found
that cells with increased levels of KRT8 in metaplastic epithelial
areas in IPF lung also co-expressed increased levels of SFN
compared to controls (Fig 6J). Thus, in summary, our in situ valida-
tion suggests that the observed negative correlation of TNC and SFN
protein in BALF is the consequence of a general upregulation of
these markers in several epithelial states within the metaplastic and
“bronchiolized” epithelium in IPF.
In summary, our cross-modality analysis serves as proof of
concept that cell state and frequency changes in diseased organs can
transpire into predictive body fluid protein signatures that can be
analyzed by mass spectrometry with high precision.
A disease associated pericyte state in ILD
One of the protein biomarkers in BALF that showed a significant
negative correlation with lung function was the Complement factor
H-related protein 1 (CFHR1) (Fig 7A). CFHR1 activates the comple-
ment system in vivo via competitive antagonism with Complement
factor H (CFH), which is a soluble inhibitor of complement (de Jorge
et al, 2013). Increased activation of complement has been reported
in IPF and was discussed to perpetuate epithelial injury (Meliconi
et al, 1990; Gu et al, 2014; Pankita & Pandya, 2014). Thus, to follow
this important lead we used our single-cell data to shed light on the
cellular source of ILD-specific upregulation of CFHR1.
Expression of CFHR1 was exclusively detectable in COL1A2+
stromal cells (Appendix Fig S7). In the COL1A2+ cells, the CFHR1
expression was further limited to an activated PDGFRB+ pericyte
state that was mainly found in ILD patients (Fig 7B). Differential
gene expression analysis within the pericyte population indeed iden-
tified CFHR1 as a top regulated gene (Fig 7C), together with many
◀ Figure 5. Protein signatures in BALF predict lung function decline and the corresponding cellular changes.
A, B The heatmaps show the deconvolution scores of cell types across BALF samples grouped by diagnosis (A) and indicated clinical parameters (B).
C, D Empirical cumulative density plots depict the distribution of correlation coefficients for (C) Myofibroblast markers (red points) with DLCO and (D) Plasma cell
markers (red points) with % alveolar macrophages in BAL in comparison to all background proteins (black line).
E Barplot displays coefficients derived from correlating lung function associations at the protein level with cell type-specific ILD associations at the RNA level.
F The heatmap illustrates gene expression changes associated with lung fibrosis across indicated cell types (columns) for selected BALF protein biomarkers (rows).
The dotplot visualizes the frequency changes of the indicated cell types inferred from the deconvolution of bulk mRNA data of ILD samples compared to controls
(GSE47460). Samples used in this study from the LTRC n = 254 ILD patients and n = 108 controls.
G The protein features in BALF were used to train a random forest algorithm to predict lung function. The model was tested on transcriptional signatures from
single-cell RNA-seq data to correctly predict reduced lung function in end-stage lung fibrosis when compared to controls.
H, I Box plots show predicted lung function changes (DLCO%) in the three single-cell RNA-seq cohorts (Chicago cohort: ILD n = 9, controls n = 8; Nashville cohort: ILD
n = 20, controls n = 10; Munich cohort: ILD n = 3, controls n = 11) in (H) and published bulk RNA-seq of IPF samples from different histopathological stages (GEO
GSE124685) (control n = 35, IPF1 n = 19, IPF2 n = 16, IPF3 n = 14) in (I). The boxes represent the interquartile range, the horizontal line in the box is the median,
and the whiskers represent 1.5 times the interquartile range.
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other genes that were significantly enriched for several gene cate-
gories, including “chemokine activity”, “G-protein-coupled recep-
tor”, and “complement regulatory” genes (Fig 7D).
The observed upregulation of the G-protein-coupled receptor
gene SSTR2 has previously been associated with ILD (Schniering
et al, 2019a), but its cell type-specific expression patterns were
unclear. To identify gene programs in pericytes that are associated
with high SSTR2 expression, we performed gene–gene correlation
analysis across single-cells. To mitigate the impact of sparse counts
on correlation measures, we aggregated cells into small clusters of
transcriptionally similar cells before calculating correlation follow-
ing previous work (Iacono et al, 2019). The correlation analysis
revealed a large cluster of genes that was strongly associated with
SSTR2 in pericytes, including CFHR1, CFH, CXCL2/3, CD36, and
YAP1 (Fig 7E). The disease-specific expression of SSTR2 in
PDGFRB+ pericytes was confirmed using immunofluorescence
microscopy (Fig 7F) and immunohistochemistry (Fig 7G). SSTR2+/
PDGFRB+/DES pericytes were found around remodeled vessels
that had a thickened layer of DES+/PDGFRB+ smooth muscle cells
in ILD. PDGFRB+/DES pericytes were negative for SSTR2 in
control lungs with normal thickness of the smooth muscle cell layer
(Fig 7F). We quantified the SSTR2 immunohistochemistry signal in
79 tissue sections from 53 ILD patients and 26 control patients, and
correlated this signal with the severity of fibrotic remodeling using
an Ashcroft scoring (Fig 7H). The SSTR2 levels were strongly asso-
ciated with high Ashcroft scores, indicating that the SSTR2+/
CFHR1+ pericyte state is correlated with the severity of fibrosis.
Gene–gene correlation analysis revealed that the transcriptional
regulator Yap1 was strongly associated with SSTR2 expression







Figure 6. Cell type-specific transcriptional ILD signatures translate into protein signatures associated with lung function in the BALF.
A, B Scatter plots stratify genes based on the protein lung function associations (y-axis) and cell type-specific ILD associations (x-axis). The size of the dots represents
the detection level of each gene in the corresponding cell type. Colors highlight genes with marginal associations at the protein and RNA levels.
C, D The box plots illustrate differences in mRNA detection for the indicated genes between tissues from end-stage lung fibrosis patients in (C) basal cells and (D)
alveolar epithelial cells when compared to controls. The boxes represent the interquartile range, the horizontal line in the box is the median, and the whiskers
represent 1.5 times the interquartile range (Chicago cohort: ILD n = 9, controls n = 8; Nashville cohort: ILD n = 20, controls n = 10; Munich cohort: ILD n = 3,
controls n = 11).
E, F The scatter plots show the positive correlation of the indicated proteins in BALF (MS-intensity, x-axis) with meta lung function (y-axis).
G–J Immunofluorescence analysis of the indicated proteins and cell type markers in IPF (n = 3) and control samples (n = 3).
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Yap1 target gene signature within the set of SSTR2 correlated genes
(Fig 7J). This prediction instead pointed toward a STAT1/NFKB-
driven inflammatory signature that could be consistent with the
many immune-associated genes (e.g., CXCL2/3) co-expressed with
SSTR2 and CFHR1 (Fig 7J).
To predict the hierarchy of gene expression during the state
change of pericytes in ILD, we performed a pseudotemporal model-
ing analysis of this differentiation trajectory (Fig 7K–M). Our model
confirmed the gradual upregulation of SSTR2 and CFHR1 with their
correlating genes (Fig 7E) concurrent with downregulation of
several pericyte marker genes such as PDGFRB (Fig 7M). Thus, in
summary we have discovered a novel ILD-associated pericyte state
that may affect pathogenesis via its influence on local complement
activation and immune cell recruitment. The appearance of this
novel SSTR2+ pericyte state is furthermore reflected by increased
levels of CFHR1 protein in the lavage fluid.
CRTAC1 is a novel peripheral protein biomarker of AT2 cell health
status in the lung
The BALF protein with the highest and most significant positive
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analysis was the cartilage acidic protein 1 (CRTAC1), whose func-
tion in the lung is currently unknown (Figs 4E and 8A). Our single-
cell atlas revealed specific expression of CRTAC1 in lung lymphatic
endothelium, airway club cells, and most prominently in alveolar
type-2 epithelial (AT2) cells (Fig 8B, Appendix Fig S7B). On the
whole body level, the mRNA expression of CRTAC1 was highest in
the lung (Fig 8C). Expression of CRTAC1 in alveolar epithelial cells
was consistently downregulated in ILD samples compared to
controls in all three patient cohorts analyzed by single-cell RNA-seq
(Fig 8D). Also re-analysis of published bulk transcriptomes con-
firmed a highly significant downregulation of CRTAC1 mRNA in the
lung of ILD patients compared to healthy controls and COPD
patients (Fig 8E).
To identify gene programs within AT2 cells that are associated
with CRTAC1 expression, we performed gene–gene correlation
analysis within SFTPC+ AT2 cells. Positively and negatively corre-
lated genes were identified and those correlations were repro-
ducible across all three cohorts (Fig 8F). Genes positively
correlated with CRTAC1 across all cohorts were significantly
enriched for categories that are consistent with a normal AT2 cell
identity, including surfactant genes, and cholesterol biosynthesis
genes. The anti-correlated genes were enriched for immune and
inflammatory processes, as well as extracellular matrix and inter-
mediate filament genes (Fig 8G).
Analysis of transcriptional regulators revealed that the expres-
sion of the transcriptional activator C/EBP-delta (CEBPD) was
highly correlated with CRTAC1 expression (Fig 8H). CEBPD expres-
sion and activity is induced by glucocorticoids and has a role in AT2
cell differentiation during lung development (Breed et al, 1997; Berg
et al, 2002). Interestingly, the levels of CRTAC1 in isolated human
AT2 cells increase upon differentiation with glucocorticoids (Ballard
et al, 2010), which are known to be essential for alveolar maturation
in lung development (Gerber, 2015). Thus, we speculate that the
downregulation of CRTAC1 in AT2 cells of ILD patients may hint at
currently uncharacterized changes in glucocorticoid signaling in
these cells. We also performed upstream regulator analysis in inge-
nuity pathway analysis (IPA) to predict the activity of transcrip-
tional regulators based on the correlated or anti-correlated gene
profiles (Fig 8I). This analysis identified ETV5 as a potential regula-
tor of the CRTAC1 correlated gene program in AT2. This is in line
with the fact that ETV5 has been shown to be essential for AT2 cell
maintenance in vivo, as deletion of Etv5 from mouse AT2 cells
produced gene and protein signatures characteristic of differentiated
alveolar type I (AT1) cells (Zhang et al, 2017). Thus, our finding
here is consistent with the notion that CRTAC1 is associated with a
normal healthy and highly differentiated AT2 cell state.
The most strongly anti-correlated transcriptional regulator to
the CRTAC1-associated gene programs in AT2 cells was the tran-
scription factor SOX4 (Fig 8H). SOX4 is regulated by various path-
ways, including TGF-beta signaling, and we recently described
Sox4 together with Nupr1 as a candidate transcriptional regulator
of AT2 cell differentiation upon lung injury in the mouse (Strunz
et al, 2020). Interestingly, the IPA upstream regulator analysis
predicted high activity of NUPR1 also in AT2 cells with low
expression of CRTAC1 (Fig 8I). NUPR1 plays a role in cell stress
responses, including DNA damage repair and regulation of the
cellular senescence program. The co-regulation of SOX4 and
NUPR1 expression and activity in both mouse and human AT2
cells in health and disease suggests that this program may have
important functions in AT2 cell de-differentiation. We show that
CRTAC1 expression is strongly anti-correlated to this de-differenti-
ation program.
We modeled the de-differentiation of human AT2 cells in ILD by
deriving a pseudotime trajectory using all SFTPC+ AT2 cells and the
aberrant basaloid cells across all three cohorts (Fig 8J). The pseudo-
time trajectory showed a gradual increase of aberrant basaloid cell
markers starting already in still SFTPC+ AT2 cells and peaking in
then SFTPC/SOX4+ aberrant basaloid cells, which also expressed
genes such as SFN and TNC that we had found to be increased in
the BALF, and the cytoskeletal protein Cornifin-alpha (SPRR1A)
(Fig 8K). Importantly, the downregulation of CRTAC1 occurs in an
early stage of this differentiation process. Even though CRTAC1
expression in AT2 is specific to humans and not observed in mice,
we find that the differentiation trajectory we modeled in human IPF
is highly similar to a differentiation trajectory observed in mice after
bleomycin injury (Fig 8L). The pseudotime trajectory of mouse AT2
◀ Figure 7. An SSTR2+/CFHR1+ pericyte state correlates with progression of fibrotic remodeling.
A The scatter plots show the positive correlation of CFHR1 in BALF (MS-intensity, x-axis) with meta lung function (y-axis).
B The UMAPs show the subset of COL1A2+ mesenchymal cells in the integrated scRNA-seq dataset, with the pericytes highlighted by the dotted line. From left to right,
the colors represent the cell type identities, disease status, expression of the pericyte markers PDGFRB and CFHR1, respectively.
C The volcano plot depicts the fold changes (x-axis) and the log10 P-values (y-axis) derived from the differential gene expression analysis using diffxpy between ILD
and controls within the subset of PDGFRB+ pericytes (outlier values truncated).
D The bar graphs show the top regulated gene categories after enrichment analysis using GO terms and UniProt keywords.
E The heatmap shows the expression of genes most strongly associated with SSTR2 expression within the pericytes (left color bar indicates significant correlation or
anti-correlation).
F Immunofluorescence analysis of SSTR2, the pericyte cell type marker PDGFRB and a marker for smooth muscle cells DESMIN in IPF (n = 3) and control samples
(n = 3).
G Representative images of immunohistochemistry analysis of SSTR2 protein expression in tissue regions (n = 474) from ILD patients (n = 53) and control patients
(n = 26).
H Correlation of immunohistochemistry signal of SSTR2 with Ashcroft scores.
I The bar graph shows the genes most strongly correlated with SSTR2 belonging to the GO category “transcription regulators”. The dotted line marks a correlation
coefficient of zero.
J The bar graph shows the top correlated transcriptional regulators, predicted by ingenuity pathway analysis (IPA) for the SSTR2 gene-gene correlations. The dotted
line marks a correlation coefficient of zero.
K Diffusion map of pericytes colored by cell type and inferred pseudotime represents pericyte differentiation.
L Diffusion map of pericytes colored by the gene expression of indicated genes.
M The line plot illustrates smoothed expression levels of the indicated genes across the pericyte pseudotime differentiation trajectory.
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cells toward the Krt8+ alveolar differentiation intermediate (ADI)
cell state (Strunz et al, 2020) shows a similar upregulation of Sox4,
Sfn, Krt8, Fn1, Tnc, and Sprr1a as observed in the human trajectory
(Fig 8M). This strongly suggests that aberrant basaloid cells in IPF
may be generated from AT2 in an attempt for regenerative repair.
Indeed, we find KRT8+/SPRR1A+/SFTPC cells in close proximity
to SFTPC+ cells in areas of limited fibrotic remodeling, which may
represent early stage disease (Fig 8N).
Clinical decisions are often based on blood biomarker analysis
(Geyer et al, 2017). To extend our analysis to the plasma proteome,
we made use of a recently established high-throughput plasma
proteomics workflow (Geyer et al, 2017, 2019; Niu et al, 2019) and
generated plasma proteomes from two independent cohorts of ILD
patients (Munich, n = 30 and Hannover, n = 81; healthy age-
matched controls, n = 30; see Dataset EV10 for clinical characteris-
tics and Dataset EV11 for plasma protein quantification). We were
able to robustly detect CRTAC1 by mass spectrometry in > 80% of
the plasma samples (Fig 8O). The Hannover cohort included more
patients with better lung function on average, with samples taken
mainly at time of initial diagnosis, while the Munich cohort
contained patients closer to end-stage disease. Thus, by construc-
tion, we did not expect a perfect match of these two cohorts. Upon
correlation with forced vital capacity (FVC %), we identified a
shared panel of proteins in both cohorts that were either positively
or negatively associated with the lung function outcome (Fig 8P).
As expected, CRTAC1 showed a positive correlation with lung func-
tion in both patient cohorts.
Finally, we investigated the relative contribution of cell types/
states to the protein biomarker signatures in plasma that correlated
with lung function (Fig 8Q). We divided the patients into two
groups representing mild and severe disease based on lung function
(FVC %) and compared these two groups with healthy controls. We
observed a gradual increase of proteins potentially derived from
lung fibroblast subsets and plasma cells as well as a gradual reduc-
tion of proteins potentially derived from lung endothelial cells, alve-
olar macrophages, AT2 cells, and mDC2 (Fig 8Q).
In conclusion, our data and analysis suggest that plasma
proteomes harbor protein biomarker signatures that report the
status of cell states in health and disease. Here, we demonstrated
that the AT2-derived CRTAC1 protein in ILD patient plasma and
BAL fluid correlates with lung function and reports the loss of AT2
cell identity during disease progression.
Discussion
The field of single-cell genomics has rapidly evolved and with the
increasing availability of cell atlases is now moving toward the mech-
anistic characterization of pathogenesis and disease progression, as
well as translational applications in medicine. We can conceptualize
interindividual variance within patient cohorts with a model in which
patients at different stages of a disease progression trajectory will
have the diseased organs in different characteristic states. Body fluids
potentially contain a composite representation of these disease stage-
specific differences of cell type/state proportions within affected
organs in the form of proteins and possibly cell-free DNA. We must
deconvolute these composite signatures in order to make predictions
about cell and tissue level changes in the patient. In this work, we
◀ Figure 8. CRTAC1 protein abundance in BALF and plasma proteomes reports AT2 cell health.
A The scatter plots show the positive correlation of CFHR1 in BALF (MS-intensity, x-axis) with meta lung function (y-axis).
B UMAP visualizes embedding of single-cells colored by gene expression for CRTAC1, which is specifically expressed in alveolar type-2 (AT2), Club and lymphatic
endothelial (Lymp_EC) cells.
C Relative expression level of CRTAC1 across human organs.
D The box plots illustrate differences in mRNA detection for CRTAC1 in alveolar epithelial cells from fibrosis patients compared to control samples across the three
indicated patient cohorts (Chicago cohort: ILD n = 9, controls n = 8; Nashville cohort: ILD n = 20, controls n = 10; Munich cohort: ILD n = 3, controls n = 11). The
boxes represent the interquartile range, the horizontal line in the box is the median, and the whiskers represent 1.5 times the interquartile range.
E Relative gene expression levels of CRTAC1 in GSE47460. Dots represent average expression in the tissue of individual patients. The line represents the mean, and error
bars show SD. CRTAC1 is significantly downregulated in ILD but not COPD patients (P-value < 0.0001) (one-way ANOVA) (control donors n = 91, ILD n = 194, COPD
n = 144).
F For each single-cell cohort, the gene–gene correlations with CRTAC1 within the SFTPC+ AT-2 cells were calculated. The indicated genes were selected based on their
common direction of correlation across cohorts.
G The bar graph shows the gene categories most strongly correlated with CRTAC1 based on “UniProt keywords”. The dotted line marks a correlation coefficient of zero.
H The bar graph shows the gene categories most strongly correlated with CRTAC1 belonging to the GO category of “transcription regulators”. The dotted line marks a
correlation coefficient of zero.
I The bar graph shows the top correlated transcriptional regulators, predicted by ingenuity pathway analysis (IPA) for the CRTAC1 gene–gene correlations. The dotted
line marks a correlation coefficient of zero.
J Diffusion map of human AT2 cells colored by cell type identity and inferred pseudotime.
K The line plot illustrates smoothed expression levels of the indicated genes across the human AT2 pseudotime trajectory.
L Diffusion map of mouse AT2 cells colored by cell type identity and inferred pseudotime.
M The line plot illustrates smoothed expression levels of the indicated genes across the (Niu et al, 2019) mouse AT2 pseudotime trajectory.
N Immunofluorescence analysis of SPRR1A, KRT8 as well as SFTPC in IPF (n = 3) and control samples (n = 2).
O A high-throughput experimental workflow for plasma proteomics (Niu et al, 2019) allowed for profiling of two independent cohorts of ILD patients (Munich, n = 30
and Hannover, n = 81; healthy age-matched controls, n = 30). All proteins quantified in plasma are shown, ranked by their abundance measured by mass
spectrometry (MS-intensity).
P The indicated proteins from the plasma analysis were selected based on their common direction of correlation with patient lung function in two independent
patient cohorts with distinct clinical characteristics.
Q The heatmap shows the predicted relative contribution of lung cell types to the association of protein biomarker signatures in plasma with lung function (forced
vital capacity—FVC). Patients were split in two groups, one with a mild decline in lung function [FVC 60–100%] and one with severe loss of lung function [FVC 20–
60%] and compared to healthy age-matched controls.
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explore this idea and predict the cellular sources of protein biomarker
profiles in body fluids. We envision training machine learning algo-
rithms with large datasets of matched single-cell genomic and fluid
proteomic or sequencing readouts derived from longitudinal
measurements in patient cohorts. This will enable the development
of new automated tools for clinical decision making (Walsh et al,
2019) and drug monitoring (Maher et al, 2019) for future predictive
and interceptive medicine (Rajewsky et al, 2020).
In idiopathic pulmonary fibrosis (IPF), the most common form of
lung fibrosis, the progressive replacement of lung parenchyma with
scar tissue leads to respiratory failure with a median survival time of
2–4 years after diagnosis. Current models of disease pathogenesis
propose that a combination of repetitive (micro)injuries to suscepti-
ble alveolar epithelial cells (AEC) with an aberrant repair response
causes pathological interactions of AEC with fibroblasts and subse-
quent accumulation of scar tissue (Kropski & Blackwell, 2019).
Human genetic data and pre-clinical models show that epithelial
injury can drive subsequent fibrosis, with a combination of genetic
predisposition and aging thought to be related to the failed regenera-
tive response in IPF. The recent discovery of a transitional stem cell
state that transiently appears in normal lung regeneration but persis-
tently accumulates in lung fibrosis enables a new perspective on
pathogenesis of IPF (Verheyden & Sun, 2020; Strunz et al, 2020;
Kobayashi et al, 2020). This transitional stem cell state in mice is
highly similar to the aberrant basaloid cells in IPF (Adams et al, 2020;
Habermann et al, 2020) and features the expression of several pro-
fibrogenic factors that may activate mesenchymal cells. We show that
the main source of CRTAC1 in the human body is the alveolar AT2
cell and that CRTAC1 is downregulated early in a de-differentiation
trajectory of AT2 cells toward the aberrant basaloid state. Our data
suggests that this cellular transition is reflected in plasma proteomes
by declining abundance of CRTAC1. We therefore propose that
CRTAC1 protein levels in plasma and lavage fluids specifically report
the AT2 cell health status. This novel biomarker is thus a promising
candidate for future prospective trials in various settings, including
monitoring the degree of distal lung involvement during virus
induced pneumonia, as currently seen in the COVID-19 pandemic.
Supporting our hypothesis, a recent preprint illustrates that CRTAC1
is downregulated in plasma of hospitalized COVID-19 patients
compared to SARS-CoV-2 negative controls (Filbin et al, 2020).
Perivascular cells have been shown to be key contributors to
organ fibrosis, including the lung (Kramann et al, 2015), and a peri-
cyte to myofibroblast transition in lung fibrosis has been proposed
(Hung et al, 2019). As our single-cell analysis demonstrates, the
previous functional studies of PDGFRB+ cells isolated from lungs
underappreciated the heterogeneity of PDGFRB+ cells, which not
only contain perivascular pericytes but also fibroblast populations
and smooth muscle cells. In this work, we discover a highly disease-
specific SSTR2+/CFHR1+ pericyte state that features a pro-inflamma-
tory phenotype with expression of various chemokines. Interestingly,
the expression of the potent complement regulatory factor CFHR1 in
this cell state may explain the previously observed deregulation of
complement in IPF. Further functional investigations on this novel
pericyte state in lung fibrosis will shed light on its potential direct
relevance in disease progression. Interestingly, visualizing radiola-
beled somatostatin analogues targeting the SSTR2 receptor have
recently been proposed for the visualization of fibrotic changes in ILD
(Lebtahi et al, 2006; Ambrosini et al, 2010; Schniering et al, 2019a).
Lung fibrosis patients experience highly diverse clinical courses,
with progression often accelerated due to acute exacerbations (AE),
associated with a high mortality (Collard et al, 2016). Efforts have
been made to find predictive biomarkers for AE and disease
outcome (Collard et al, 2010; Neighbors et al, 2018). For instance,
elevated serum levels of AT2-derived SP-A and SP-D are associated
with an increased risk of mortality in IPF (Greene et al, 2002; Kinder
et al, 2009; Collard et al, 2010). CCL18 has been reported to be
elevated in the serum and BALF in patients with lung fibrosis
(Prasse et al, 2007), which we also confirm in this study. In fact, a
recent pooled post hoc analysis of the CAPACITY and ASCEND stud-
ies identified CCL-18 as the most robust blood marker for disease
progression in IPF (Neighbors et al, 2018). Nevertheless, such
biomarkers are currently not clinically established and often it is
unclear which cellular changes they represent. While early detection
of AE is currently of major interest, there are also patients who
present with clinical worsening without meeting the criteria for AE.
A daily home spirometry study resulted in highly diverse lung func-
tion trajectories in IPF (Russell et al, 2016), suggesting that lung
function diversity could also reflect different stages after epithelial
lung injury with phases of decreased lung function (potentially
being a phase of subclinical injury/exacerbation) followed by
phases of slightly increased lung function (potentially being a phase
of successful tissue repair).
Our machine learning analysis demonstrates that correspondence
of fluid proteomes and single-cell transcriptomes can be used to
correctly predict the direction of lung function changes across
modalities. The BALF proteome signature used to train the random
forest algorithm correctly predicted declining lung function across
data modalities in a micro-CT staged histopathological progression
from very early structural changes to complete fibrotic remodeling.
This indicates that the protein features derived from this large
heterogeneous patient cohort would likely also correctly report
disease progression in a longitudinal setting. This justifies further
development of this concept, which we hope will contribute to
future clinical decision making. Our work has several limitations
that prohibited us from fully completing this task. Since the cross-
modal analysis was done on non-matched patient cohorts, it is
currently difficult to assess the specificity of fluid proteome signa-
tures for tissue level cell state changes, and to go beyond associative
signatures. Thus, carefully designed longitudinal multi-modal analy-
sis of animal models and patient cohorts will be required to train
machine learning algorithms, in particular causal inference models,
for future applications in predictive personalized medicine.
Materials and Methods
Human samples
Human samples of the Munich cohorts (tissue, BAL fluid and
plasma) were obtained from the bioArchive of the Comprehensive
Pneumology Center Munich (CPC-M). Written informed consent
was obtained from all patients, and the study was approved by the
local ethics committee of the Ludwig-Maximilians University of
Munich, Germany (EK 333-10 and 382-10). ILD lung tissue for
single-cell analysis was freshly obtained after lung transplantation
at the University Hospital Munich and compared to lung tissue of
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non CLD patients as tumor free, uninvolved lung tissue freshly
obtained during tumor resections performed at the lung specialist
clinic “Asklepios Fachkliniken Munich-Gauting”. BAL fluid samples
of the BAL fluid cohort and matched plasma samples were collected
at the lung specialist clinic and included mainly first ILD evalua-
tions. Plasma samples from an independent ILD cohort were
obtained from patients seen in the ILD outpatient clinic of the Hospi-
tal of the Ludwigs Maximilian University in Munich during routine
visits or as an inpatient during evaluation for lung transplantation.
Plasma samples of the Hannover cohort were obtained as a coopera-
tion within the German Center for Lung Research (DZL); patients
gave written informed consent (DZL broad-consent), and the study
was approved by the local ethics committee of the Medizinische
Hochschule Hannover (2923-2015). For the histology sections of the
SSTR2 histochemistry and Ashcroft scoring, the local ethics commit-
tee of the University Hospital Z€urich approved the study (BASEC-
No. 2017-01298), and informed consent was obtained from all
patients. Informed consent was obtained from all subjects, and the
experiments conformed to the principles set out in the WMA Decla-
ration of Helsinki and the Department of Health and Human
Services Belmont Report.
The diagnosis of IPF was made in accordance with the current
guidelines (Raghu et al, 2015). All ILD diagnoses were made accord-
ing to international guidelines and established criteria. Non-ILD
patients of the BAL fluid cohort included patients who underwent
BAL due to evaluation of asthma, COPD, lung cancer, hemoptysis,
or chronic cough.
For transport from the operation room to the laboratory, lung
tissue samples for single-cell analysis were stored in ice-cold
DMEM-F12 media in thermo stable boxes. Tissue was processed for
single-cell analysis with a maximum delay of 2 h after surgery.
Lung tissue processing
Lung tissue was processed as previously described (Vieira Braga
et al, 2019). Briefly, around 1.5 g of tissue per sample was manually
homogenized into smaller pieces (~ 0.5 mm2 per piece). Before
tissue digestion, lung homogenates were cleared by washing exces-
sive blood through a 40-lm strainer with ice-cold PBS. The tissue
was transferred into enzyme mix consisting of dispase, collagenase,
elastase, and DNase for mild enzymatic digestion for 1 h at 37°C
while shaking. Enzyme activity was inhibited by adding PBS supple-
mented with 10% FCS. Dissociated cells in suspension were passed
through a 70-lm strainer and pelleted. The cell pellet was resus-
pended in red blood cell lysis buffer and incubated shortly at room
temperature to lyse remaining red blood cells. After incubation, PBS
supplemented with 10% FCS was added to the suspension and the
cells were pelleted. The cells were taken up in PBS supplemented
with 10% FCS, counted using a Neubauer chamber, and critically
assessed for single-cell separation and viability. Two-hundred and
fifty thousand cells were aliquoted in PBS supplemented with
0.04% of bovine serum albumin and loaded for Drop-seq at a final
concentration of 100 cells/ll.
Single-cell sequencing using Drop-seq
Drop-seq experiments were performed largely as described previ-
ously (Macosko et al, 2015) with few adaptations during the single-
cell library preparation (Angelidis et al, 2019). Briefly, using a
microfluidic polydimethylsiloxane device (Nanoshift), single-cells
from the lung cell suspension were co-encapsulated in droplets with
barcoded beads (ChemGenes). Droplet emulsions were collected for
15 min each before droplet breakage was performed using perfluo-
rooctanol (Sigma-Aldrich). After breakage, beads were collected and
the hybridized mRNA transcripts reverse transcribed (Maxima RT,
Thermo Fisher). Unused primers were removed by the addition of
exonuclease I (New England Biolabs). Beads were washed, counted,
and aliquoted for pre-amplification with 12 PCR cycles (primers,
chemistry, and cycle conditions identical to those previously
described). PCR products were pooled and purified twice by 0.6×
clean-up beads (CleanNA). Before tagmentation, cDNA samples
were loaded on a DNA High Sensitivity Chip on the 2100 Bioana-
lyzer (Agilent) to ensure transcript integrity, purity, and amount.
For each sample, 1 ng of pre-amplified cDNA from an estimated
1,000 cells was tagmented by Nextera XT (Illumina) with a custom
P5 primer (Integrated DNA Technologies). Single-cell libraries were
sequenced in a 100 bp paired-end run on the Illumina HiSeq 4000
using 0.2 nM denatured sample and 5% PhiX spike-in. For priming
of read 1, 0.5 lM Read1CustSeqB (primer sequence: GCCTGTC
CGCGGAAGCAGTGGTATCAACGCAGAGTAC) was used.
Processing of single-cell data from Munich
For the single-cell data of human patients form the Munich cohort,
the Drop-seq computational pipeline was used (version 2.0) as
previously described (Macosko et al, 2015). Briefly, STAR (version
2.5.2a) was used for mapping (Dobin et al, 2013). Reads were
aligned to the hg19 reference genome (GSE63269). For barcode fil-
tering, we excluded barcodes with less than 200 detected genes. For
further filtering, we kept the top barcodes based on UMI count per
cell, guided by the number of estimated cells per sample. As we
observed a certain degree of ambient RNA bias, we applied SoupX
(Young & Behjati, 2020) to lessen this effect. The pCut parameter
was set to 0.3 within each sample before merging the count matrices
together. The merged expression table was then pre-processed
further. A high proportion (> 10%) of transcript counts derived
from mitochondria-encoded genes may indicate low cell quality,
and we removed these unqualified cells from downstream analysis.
Cells with a high number of UMI counts may represent doublets;
thus, only cells with less than 4000 UMIs were used in downstream
analysis. Genes were only considered if they were expressed in at
least three cells in the dataset (Dobin et al, 2013).
Analysis of single-cell data from Munich
The downstream analysis of the Munich single-cell data was
performed using the Scanpy Package (Wolf et al, 2018), a python
package for the exploration of single-cell RNA-seq data. Following
the common procedure, the expression matrices were normalized
using scran’s (Lun et al, 2016) normalization based on size factors
which are calculated and used to scale the counts in each cell. Next
log transformation was used via scanpy’s pp.log1p(). Highly variable
genes were selected as follows. First, the function pp.highly_vari-
able_genes() was executed for each sample separately, returning the
top 4,000 variable genes per sample. Next, we only considered a gene
as variable if it was labeled as such in at least two samples, resulting
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in a total of 15,096 genes which were further used for the principal
component analysis. In an additional step to mitigate the effects of
unwanted sources of cell-to-cell variation, we regressed out the
number of UMI counts, percentage of mitochondrial DNA and the
calculated cell cycle score using the function pp.regress_out().
For visualizing the whole Munich dataset, the UMAP was gener-
ated using 50 components as input for scanpy’s tl.umap() with
number of neighbors set to 10 and min_dist parameter to 0.4. To
better align the data of the different patients and to account for
possible batch effects, we used the python package bbknn() (batch
balanced k nearest neighbors) (Polanski et al, 2020) with the same
number of components and neighbors. Louvain clustering was
calculated with resolution 6. The whole lung parenchymal dataset
was split into subsets for COL1A2+ mesenchymal cells, EPCAM+
epithelial cells, CLDN5+ endothelial cells, and PTPRC+ leukocytes.
New UMAP embeddings of these subsets were calculated until clear
separation of cluster identities was achieved that allowed for identi-
fication of cell states by exploring the highest expressed markers per
cluster explored via tl.rank_genes_groups() and manual assessment
of known marker gene expression.
Computational data integration of single-cell data
To improve statistical power, to ensure generalization across cohorts
and to achieve a more balanced ratio of diseased and healthy
patients, our Munich single-cell RNA-seq dataset was combined with
the filtered count matrices from the Chicago cohort (Reyfman et al,
2019) and the Nashville cohort.
Before combining these, the count matrices from Chicago and
Nashville were processed separately. The normalization using scran
and the log transformation of the two external datasets was
performed as described for the Munich cohort. The effect of cell
cycle, the percentage of mitochondrial reads, and the number of
UMI counts were regressed out cohort-wise as well.
For a first lighter batch correction, we defined the list of variable
genes in a way to decrease cohort-specific effect as follows. For both
the Nashville and the Chicago data, we considered a gene as highly
variable if it is labeled highly variable in at least three patients of
the respective dataset. Next, the pre-processed count matrices from
the three datasets were merged and genes retained their highly vari-
able status if they were highly variable in at least two of the three
cohorts, resulting in 3,854 variable genes.
The concatenated object was scaled with scanpy’s pp.scale()
function, and the principal components were calculated using the
defined variable genes. As a second batch correction, we calculated
the neighborhood graph using the bbknn package, defining the indi-
vidual patients as batch key, five number of neighbors within batch
and 40 components. As described for the Munich cohort, the whole
combined object was subsetted and new embeddings were calcu-
lated in order to identify cell states.
Differential gene expression analysis
To identify genes associated with ILD status in a cell type-specific
manner, we applied the following procedure. The R statistical soft-
ware was used for the analysis. Since the outcome of interest (ILD
status) varies at the sample (n = 61) as opposed to the cell level
(n = 233,638), we framed the analysis as a likelihood of detection
problem across all samples. For each sample and cell type combina-
tion, we calculated the likelihood of detection for each gene as the
average number of cells with more than one count. As the likelihood
of detection represents a probability and is bounded between 0 and
1, values were square-root transformed. Next, we used multivariate
regression to model the probabilities of detection. The square-root
transformed detection probability was used as the dependent vari-
able and the ILD status or gender as the explanatory variable
accounting for the total number of UMI counts, total number of cells,
study indicator, age and gender as covariates. The resulting t and P-
values for the coefficient describing the ILD status or gender were
used in downstream analysis. Due to the relatively low number of
pericytes, differential expression analysis within pericytes was
performed using diffxpy (https://github.com/theislab/diffxpy).
Cell type signature enrichment analysis
To infer cell type frequency changes from bulk transcriptomics or
proteomics data, we applied signature enrichment analysis. We
defined cell type signatures as sets of genes with significant cell
type-specific expression as defined in Dataset EV2. Next, we statisti-
cally evaluated enrichment of each signature in a ranked list of fold
changes or correlation coefficients using the Kolmogorov–Smirnov
test. The signed P-value score represents the log10 P-value of the
Kolmogorov–Smirnov test signed by the effect size. Negative and
positive values represent depletion and enrichment of the given
signature in the ranked list, respectively.
Random forest prediction
To integrate scRNA-seq with BALF data, we used a random forest as
implemented in the R randomForest package. First, BALF expression
data were quantile normalized and scaled. Next, only features with
an absolute correlation coefficient greater than 0.2 with lung func-
tion and present in the scRNA-seq data were used to train a random
forest to predict lung function. Then, in silico bulk scRNA-seq was
calculated by taking the mean expression count of each gene across
all cells for all samples. Finally, the in silico bulk data were quantile
normalized and scaled before feeding it into the trained model to
predict lung function. In addition, we applied the analogous
approach with the bulk RNA-seq data of IPF samples from different
histopathological stages determined by quantitative micro-CT imag-
ing and tissue histology (GEO GSE124685).
Gene–gene correlation analysis
The gene–gene correlation analysis followed the approach described
by Iacono et al (Iacono et al, 2019). More precisely, the subsets of peri-
cytes and AT2 cells were used for each analysis independently. Princi-
pal components were recalculated and subjected to Louvain
clustering using a relatively high-resolution parameter in order to
derive a relatively large number of transcriptionally similar cell clus-
ters. Next, expression across these cell clusters was averaged. Pearson
correlation coefficients were calculated across these meta-cell cluster
averages to derive the gene-gene correlations. Averaging the expres-
sion across small numbers of cells mitigates the impact of sparse
counts at the single-cell level and leads to increased correlation
values.
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Pseudotime analysis
To model the gene expression dynamics underlying the ILD-specific
pericyte and AT2 trajectories, the following analysis was performed.
Data were subset to pericytes or AT2 cells, and each subset was
analyzed independently. Principal components were recalculated.
Subsequently, a diffusion map was derived based on the principal
components and pseudotime coordinates were calculated using the
Scanpy function sc.tl.dpt(). To visualize gene expression along the
inferred trajectory, pseudotime coordinates were divided into
equally sized bins and expression values were averaged within each
bin. A smooth fit was calculated across these expression averages
and displayed using line plots.
Clinical parameters
For all patients included in the final analysis, clinical information
was collected at the time of BAL fluid procedure or when plasma
was taken, respectively. Clinical parameters included demographics
(age, gender, smoking status, pack years, smoking abstinence, lung
function [forced vital capacity (FVC) (% pred.), FVC (l), FVC (post-
broncholysis), expiratory reserve volume (ERV), forced expiratory
volume in 1 s (FEV1) (l), FEV1/FVC (%), inspiratory capacity (IC)
(l), total lung capacity (TLC) (l), TLC from baseline, residual volume
(RV), RV (%TLC), diffusing capacity of the lung for carbon monox-
ide (DLCO) (VA) (mmol/min/kPa/l), DLCO (SB) (% pred.), DLCO
(SB) (Hb corrected, % pred.), DLCO (SB) (mmol/min/kPa), mean
expiratory flow (MEF) 25, MEF50, intrathoracic gas volume
(ITGV)], laboratory values [cholinesterase, alkaline phosphatase, C-
reactive protein, alanine-aminotransferase (ALT), aspartate-amino-
transferase (AST), gamma-glutamyltransferase (GGT), LDH].
BAL procedure
BALF was collected from 141 patients undergoing bronchoscopy
from January 2013 until March 2016 at the Lungenfachklinik Gaut-
ing in Munich, Germany. Most of the patients underwent bron-
choscopy due to ILD evaluation. BAL was performed with standard
technique. In brief, 100–200 ml of sterile saline (0.9% NaCl) was
instilled into the right middle lobe or the lingula in 20-ml injections
which were each immediately aspirated. Cells of the BAL were
analyzed by cytospin analysis. The remaining cell-free BAL fluid
was immediately stored at 80°C and transferred to the BioArchive
of the CPC-M. For mass spectrometry, only the cell-free BAL fluids
were analyzed. Of the 141 patients, only 124 passed quality control
and were included in the analysis (95 ILD and 29 non-ILD).
Mass spectrometry
The BAL fluid depleted from cells was subjected to mass spectrome-
try analysis. Proteins were precipitated from 300 µl BAL fluid using
80% ice-cold acetone, followed by reduction and alkylation of
proteins and overnight digestion into peptides using Trypsin and
LysC proteases (1:100) as previously described (Schiller et al, 2015).
Peptides were purified using StageTips containing a Poly-styrene-
divinylbenzene copolymer modified with sulfonic acid groups (SDB-
RPS) material (3 M, St. Paul, MN 55144-1000, USA) as previously
described (Kulak et al, 2014). Approximately 2 lg of peptides were
separated in 4 h gradients on a 50-cm long (75-lm inner diameter)
column packed in-house with ReproSil-Pur C18-AQ 1.9 lm resin (Dr.
Maisch GmbH). Reverse-phase chromatography was performed with
an EASY-nLC 1000 ultra-high pressure system (Thermo Fisher Scien-
tific), which was coupled to a Q Exactive Mass Spectrometer (Thermo
Scientific). Peptides were loaded with buffer A (0.1% (v/v) formic
acid) and eluted with a non-linear 240-min gradient of 5–60% buffer
B (0.1% (v/v) formic acid, 80% (v/v) acetonitrile) at a flow rate of
250 nl/min. After each gradient, the column was washed with 95%
buffer B and re-equilibrated with buffer A. Column temperature was
kept at 50°C by an in-house designed oven with a Peltier element
(Thakur et al, 2011), and operational parameters were monitored in
real time by the SprayQC software (Scheltema & Mann 2012). MS
data were acquired with a shotgun proteomics method, where in
each cycle a full scan, providing an overview of the full complement
of isotope patterns visible at that particular time point, is follow by
up-to ten data-dependent MS/MS scans on the most abundant not yet
sequenced isotopes (top10 method) (Michalski et al, 2011). Target
value for the full scan MS spectra was 3 × 106 charges in the
3001,650 m/z range with a maximum injection time of 20 ms and a
resolution of 70,000 at m/z 400. The resulting mass spectra were
processed using the MaxQuant software (Cox & Mann, 2008), which
enabled label free protein quantification (Tyanova et al, 2016).
Plasma samples were prepared with the Plasma Proteome Profil-
ing Pipeline (Geyer et al, 2016) automated on an Agilent Bravo
liquid handling platform. Briefly, plasma samples were diluted 1:10
in ddH2O and 10 µl were mixed with 10 µl PreOmics lysis buffer
(P.O. 00001, PreOmics GmbH) for reduction of disulfide bridges,
cysteine alkylation, and protein denaturation at 95°C for 10 min.
Trypsin and LysC were added at a ratio of 1:100 micrograms of
enzyme to micrograms of protein after a 5 min cooling step at room
temperature. Digestion was performed at 37°C for 1 h. An amount
of 20 µg of peptides was loaded on two 14-gauge StageTip plugs,
followed by consecutive purification steps according to the PreO-
mics iST protocol (www.preomics.com). The StageTips were centri-
fuged using an in-house 3D-printed StageTip centrifugal device at
1,500 g. The collected material was completely dried using a
SpeedVac centrifuge at 60°C (Eppendorf, Concentrator plus).
Peptides were suspended in buffer A* (2% acetonitrile (v/v), 0.1%
formic acid (v/v)) and shaking for 10 min at room temperature.
Plasma peptides were measured using LC-MS instrumentation
consisting of an Evosep One (Evosep), which was online coupled to
a Q Exactive HF Orbitrap (Thermo Fisher Scientific). Peptides were
separated on 15 cm capillary columns (ID: 150 µm; in-house packed
into the pulled tip with ReproSil-Pur C18-AQ 1.9 µm resin (Dr.
Maisch GmbH)). For each LC-MS/MS analysis, about 0.5 µg
peptides were loaded and separated using the Evosep 60 samples
method. Column temperature was kept at 60°C by an in-house-
developed oven containing a Peltier element, and parameters were
monitored in real time by the SprayQC software. MS data were
acquired with data independent acquisition using a full scan at a
resolution of 120,000 at m/z 200, followed by 22 MS/MS scans at a
resolution of 30,000.
Mass spectrometry bioinformatic and statistical analyses
MS raw files of the plasma samples were analyzed by Spectronaut
software [version 12.0.20491.10.21239 (Bruderer et al, 2015; Geyer
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et al, 2016)] from Biognosys with default settings applied and were
searched against the human UniProt FASTA database. Mass spec-
trometry raw files of the BALF samples were processed using the
MaxQuant software (Cox & Mann, 2008) (version 1.5.3.34). As
previously described (Schiller et al, 2015), peak lists were searched
against the human UniProt FASTA database (November 2016), and
a common contaminants database (247 entries) by the Andromeda
search engine (Cox et al, 2011). Pearson correlation analysis, t-test
statistics, ANOVA tests, or Fisher’s exact test were performed using
the GraphPad Prism 5 software. To identify proteins associated with
lung function, the following procedure was used. Since a small frac-
tion of samples contained missing values, principal component anal-
ysis, as implemented in the imputePCA() function of the missMDA
R package, was used to derive a single “meta” lung function vari-
able. Missing values in the BALF protein expression were imputed
using the missForest() function of the missForest R package.
Imputed values were used to model meta lung function accounting
for covariates age and gender. The multivariate regression was
implemented using the lm() function. P-values were adjusted for
multiple testing using the R p.adjust() function. All other statistical
and bioinformatics operations (such as normalization, data integra-
tion, annotation enrichment analysis, correlation analysis, hierarchi-
cal clustering, principal component analysis, and multiple-
hypothesis testing corrections) were run with the Perseus software
package (version 1.5.3.0 and 1.6.1.1.) (Tyanova et al, 2016).
Immunofluorescence and microscopy
Formalin-fixed paraffin-embedded (FFPE) lung sections (3.5 lm
thick) from ILD patients and controls were stained as previously
described. In brief, after deparaffinization, rehydration, and heat-
mediated antigen retrieval with citrate buffer (10 mM, pH = 6.0),
sections were blocked with 5% bovine serum albumin for 1 h at
room temperature followed by overnight incubation with the
following primary antibodies at 4°C: rabbit anti-TNC (abcam,
ab108930, 1:100), rabbit anti-SPRR1A (abcam, ab125374, 1:2,000),
rabbit anti-SFTPC (Sigma-Aldrich, HPA010928 1:150), rabbit anti-
SSTR2 (abcam, ab134152, 1:50), rabbit anti-YAP (abcam,
ab205270, 1:500), rat anti-KRT8 (University of Iowa Hybridoma
Bank, 1:200), mouse anti-PDGFRb (Origene, TA506230, 1:50),
mouse anti-SFTPC (Santa Cruz Biotechnologies, sc-518029, 1:50),
chicken anti-Krt5 (BioLegend, Poly9059, 1:1,000), goat anti-SFN
(abcam, ab77187, 1:250), goat anti-DES (Santa Cruz Biotechnolo-
gies, sc-7559, 1:100), and goat anti-CD45 (LifeSpan Biosciences,
LS‑B14248, 1:300). For visualization of stainings, the following
secondary antibodies were used: donkey anti-rabbit Alexa Fluor
488 (Invitrogen, A-21206, 1:250), donkey anti-rat Alexa Fluor 488
(Invitrogen, A21208, 1:250), donkey anti-mouse Alexa Fluor 488
(Invitrogen, A21202, 1:250), goat anti-chicken Alexa Fluor 568
(Invitrogen, A11041, 1:250), donkey anti-rabbit Alexa Fluor 568
(Invitrogen, A10042, 1:250), donkey anti-rabbit Alexa Fluor 647
(Invitrogen, A31573, 1:250), goat anti-mouse Alexa Fluor 647
(Invitrogen, A21236, 1:250), and donkey anti-goat Alexa Fluor 647
(Invitrogen, A21447, 1:250). Tissue sections were additionally
stained with 4’,6-diamidino-2-phenylindole (DAPI, 10 mins at room
temperature) to visualize cell nuclei, and tissue autofluorescence
was blocked using the Vector TrueVIEW Autofluorescence Quench-
ing Kit (Vector Laboratories).
Immunofluorescent images were recorded on an AxioImager.M2
microscope (Zeiss) using a Plan-Apochromat 20×/0.8M27 objective.
Immunohistochemical analysis of SSTR2 expression
Immunohistochemistry of SSTR2 on FFPE lung sections from ILD
patients (n = 53) and controls (n = 26) was performed as previously
described (Schniering et al, 2019a) using an automated single-stain-
ing procedure (Benchmark Ultra; Ventana Medical Systems) and a
rabbit anti-SSTR2 antibody (abcam, ab134152, 1:50). Detection was
finalized with respective secondary antibodies and the OptiView
DAB Kit (Ventana Medical Systems). Images were acquired with the
AxioScan.Z1 slidescanner (Zeiss) using a Plan-Apochromat 20×/0.8
M27 objective. For quantification of SSTR2 tissue expression, six
randomly selected high power fields were taken per sample with the
Zen 2.0 lite (blue edition) software and the percentages of positively
stained pixels were automatically quantified using an in-house
designed MATLAB script (MathWorks, MATLAB R2016b). For
correlation of SSTR2 expression with the extent of lung fibrosis on
the tissue level, the Ashcroft score was applied on adjacent picrosir-
ius red-stained lung sections as previously described (Schniering
et al, 2018, 2019b), and Pearson correlation analysis with SSTR2
tissue expression was performed.
The paper explained
Problem
Future personalized interceptive medicine wants to assess early onset
of disease in a pre-clinical stage when the patient is still feeling
healthy. To work toward this goal, we must understand the changes
to cellular circuits in patient organs early in disease. Furthermore, we
must know how these changes are reflected in easy-to-access body
fluids that can be used for straightforward longitudinal sampling and
surveillance.
Results
In this work, the authors have established a proof of concept showing
that data transfer between single-cell transcriptomic and body fluid
proteomic modalities is possible. They identify specific gene expression
and frequency changes on cell type level and use histopathologically
staged data to infer early changes in lung fibrosis patients. Using
machine learning, they demonstrate that protein signatures in lung
lavage fluids correlating with lung function in a large cohort of lung
fibrosis patients correspond with specific cell state and cell frequency
changes in disease progression. Specifically, the study identifies an
activated pericyte state that correlates with disease severity and
shows that its presence is reflected by the complement regulatory
factor CFHR1 in lung lavage fluid. The authors also discover that the
de-differentiation of alveolar type-2 epithelial cells in lung fibrosis is
reflected by lung lavage fluid and blood plasma levels of the protein
CRTAC1, thus establishing a novel peripheral protein biomarker of the
lung alveolar epithelial health status.
Impact
This work provides an integrated single-cell atlas of human lung
fibrosis and establishes the correspondence of a set of peripheral
protein biomarker signatures with cellular changes in the lung. The
clinical utility of these novel biomarker signatures in monitoring
disease progression can be addressed in prospective longitudinal
follow-up studies. Conceptually, this study serves as important proof
of concept for non-invasive cell state monitoring for future intercep-
tive medicine.
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Data availability
Count tables of the Munich single-cell cohort as well as all custom
analysis code can be accessed at https://github.com/theislab/2020_
Mayr. Proteome raw data and MaxQuant processing tables can be
downloaded from the PRIDE repository under the accession
numbers PXD017145 (http://www.ebi.ac.uk/pride/archive/projec
ts/PXD017145) (BALF) and PXD017210 (http://www.ebi.ac.uk/
pride/archive/projects/PXD017210) (plasma).
Expanded View for this article is available online.
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